RecruitingPhase 2Phase 3NCT07576868

A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)

A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) / Dengue and Dengue-like Illness Patients (Part 2)

Sponsor

Hyundai Bioscience Co., Ltd.

Enrollment

210 participants

Start Date

Apr 9, 2026

Study Type

INTERVENTIONAL

Conditions

Dengue

Summary

This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Patients who are 18 years or over of age at time of screening.
Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.
Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)

Exclusion Criteria3

Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)
Patients who have previously received dengue vaccine
Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease

Interested in this trial?

Get notified about updates and connect with the research team.